ACCP is pleased to offer satellite symposia as a forum for the presentation of industry-sponsored educational programs during the Annual Meeting. Acceptable educational formats for satellite symposia include presentations by speakers, panel discussions, films, and video presentations. Attendance at a satellite symposium will range from 75 to 200 attendees, depending on the topic and concurrent symposia. The following programs are available for continuing pharmacy education credit, and there is no fee to attend.

Sunday, October 19

Registration and Lunch: 12:00 p.m. – 1:00 p.m.
Satellite Symposium 1:00 p.m. – 3:00 p.m.

Location:
Louisville Marriott Downtown
Marriott Ballroom V, 2nd floor

Program Overview:
Osteoporosis has a significant health impact in the United States, leading to millions of patients taking oral bisphosphonates for the treatment of osteoporosis every year. Although these medications are widely used, recent literature has reported important considerations for the use of this class of agents. Clinical pharmacists have a key role educating patients, students, residents, and other health care providers; therefore, timely information regarding the clinical application of recent literature on the use of bisphosphonates is appropriate and necessary. This two-hour accredited symposium will provide participants with an overview of osteoporosis and a discussion of the recently released fracture risk assessment tool (the WHO FRAX™ model), as well as a review of bisphosphonate pharmacology. Faculty will also examine the most recent literature regarding the use of bisphosphonates and discuss considerations for their use long term. The symposium will conclude with clinical case reviews and an open question and answer session between the faculty and audience.

Educational Objectives:

1. Describe the use and incorporation of the FRAX™ model into clinical practice as a tool to guide osteoporosis therapy.
2. Compare and contrast the differences between bisphosphonates based on pharmacokinetics and the possible clinical implications of these differences.
3. Apply literature results on bisphosphonates and osteoporosis to clinical practice.

Agenda & Faculty:
Welcome, Introduction, and Program Overview

Review of Osteoporosis and the FRAX™ Model
Michael R. McClung, M.D., FACP
Director, Oregon Osteoporosis Center
Portland, Oregon

Bisphosphonate Pharmacology Review
Elena Umland, Pharm.D.
Associate Dean for Academic Affairs
Jefferson School of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania

Bisphosphonate Use in Clinical Practice
Michael R. McClung, M.D., FACE, FACP

Long-Term Use of Bisphosphonate Therapy–Safety Considerations
Elena Umland, Pharm.D.

Clinical Case Discussion/Question & Answer Session
Michael R. McClung, M.D., and Elena Umland, Pharm.D.

Continuing Education Credit:
2.0 contact hours (0.2 CEUs) of continuing pharmacy education credit

Registration Information:
ONLINE: Register online at http://www.ceconcepts.net/bisphosphonates
PHONE: Call Lucia Denton at (866) 360-1717, between the hours of 8:30 a.m. and 5:30 p.m. Eastern time, Monday through Friday. Messages can be left after hours.

This program is supported by an independent educational grant from the Alliance for Better Bone Health, Procter and Gamble Pharmaceuticals, and Aventis Pharmaceuticals, a member of the sanofi-aventis Group.

Registration and Lunch: 12:30 p.m. – 1:00 p.m.
Satellite Symposium: 1:00 p.m. – 3:00 p.m.

Location:
Louisville Marriott Downtown
Kentucky Ballroom E, 1st floor

Program Overview:
Coronary heart disease (CHD) and acute coronary syndrome (ACS) are common and costly causes of morbidity and mortality in the United States. In 2005, more than 1.4 million Americans were hospitalized with ACS. The estimated direct medical costs and indirect costs for lost productivity, morbidity, and mortality from CHD in the United States will exceed $156 billion in 2008.

Anticoagulant and antiplatelet therapies play an important role in the management of ACS. Evidence-based guidelines for the management of ACS that address anticoagulant and antiplatelet therapies are available from the American College of Cardiology (ACC), the American Heart Association (AHA), and the American College of Chest Physicians. Recent updates to these guidelines reflect the results of studies comparing therapeutic regimens involving antiplatelet and anticoagulant therapies. Clinical pharmacists play a pivotal role in the application of evidence-based guidelines to clinical practice in the management of patients with ACS.

This symposium is planned to aid clinical pharmacists in applying knowledge and best available evidence to patient care. Faculty will lead participants in a discussion of patient cases developed to address common challenges and controversies in the management of patients with ACS. In addition to active patient case discussion, an automated audience response system will be used. Participants will be encouraged to engage in oral dialog with the faculty by posing questions or challenging the conclusions.

Educational Objectives:

1. Recommend appropriate medication therapy for a patient with ACS and explain the scientific basis for the recommendations.
2. Identify a controversial issue pertaining to anticoagulant or antiplatelet therapy for a patient with ACS and discuss recent clinical evidence that helps clarify the issue.
3. Incorporate into clinical practice the recommendations for medication therapy in the ACC/AHA guidelines for the management of patients with ACS to improve clinical outcomes.

Agenda & Faculty:
Welcome and Introduction

Case Presentations and Discussion
Sarah A. Spinler, Pharm.D., FCCP, BCPS (AQ Cardiology)
Professor of Clinical Pharmacy
Philadelphia College of Pharmacy
University of the Sciences in Philadelphia
Philadelphia, Pennsylvania

Zachary A. Stacy, Pharm.D., BCPS
Associate Professor of Pharmacy Practice
St. Louis College of Pharmacy
St. Louis, Missouri

Toby C. Trujillo, Pharm.D., BCPS (AQ Cardiology)
Associate Professor of Clinical Pharmacy
University of Colorado Denver – School of Pharmacy
Clinical Coordinator
University of Colorado Hospital
Denver, Colorado

Question & Answer Session

Registration Information:
ONLINE: Register online at www.ashpadvantage.com/accp08

Planned and conducted by ASHP Advantage. Supported by an educational grant from sanofi-aventis U.S.

Monday, October 20

Registration and Breakfast: 6:15 a.m. – 7:00 a.m.
Satellite Symposium: 7:00 a.m. – 9:00 a.m.

Location:
Louisville Marriott Downtown
Kentucky Ballroom E, 1st floor

Program Overview:
This satellite symposium will use a case-based approach to focus participants on the pharmacologic issues faced by health care providers involved in the care of the elderly atherothrombotic patient as physicians try to reduce the risk of a subsequent ischemic stroke or myocardial infarction (MI). A focus of the discussion will be the role of the pharmacist, as a member of the health care team, and how to best to convey the age-specific factors that must be considered in the elderly atherothrombotic patient. After an initial case presentation of an elderly patient presenting with peripheral artery disease (PAD), the group will be asked to select the antiplatelet therapy that is most appropriate for this patient. The attendees will be asked to respond as if they are in their practice setting faced with a consultation request for a specific elderly patient.

Educational Objectives:

1. Evaluate the benefit of reducing the risk of MI and stroke subsequent to a diagnosis of atherothrombosis in the elderly and the need for early and aggressive management.
2. Consult with health care providers for the elderly and help them apply guideline recommendations for the management of patients with atherothrombosis to reduce the risk of MI and stroke.
3. Demonstrate an understanding of the clinical indications, efficacy, and potential complications related to current and emerging antiplatelet pharmacologic therapy in the elderly patient.
4. Effectively engage in dialog with health care providers so they understand the different risks and benefits associated with the use of antiplatelet agents in the elderly.

Agenda & Faculty:
Introduction and Case Presentation
Tracy E. Macaulay, Pharm.D., BCPS
Clinical Pharmacy Specialist–Cardiology
Adjunct Assistant Professor
University of Kentucky
Lexington, Kentucky

Pharmacologic Considerations Specific to the Elderly
Tracy E. Macaulay, Pharm.D., BCPS

Current and Future Antiplatelet Treatment Options for Risk Reduction
Paul Dobesh, Pharm.D., BCPS-AQ Cardiology
Associate Professor
Department of Pharmacy Practice
College of Pharmacy
University of Nebraska Medical Center
Omaha, Nebraska

Issues Affecting Choice of Antiplatelet Therapy in the Elderly
Anna M. Wodlinger Jackson, Pharm.D., BCPS
Clinical Assistant Professor
Temple University School of Pharmacy
Philadelphia, Pennsylvania

The Pharmacist’s Role in the Care of the Elderly Atherothrombotic Patient
Tracy E. Macaulay, Pharm.D., BCPS

Question & Answer Session

Intended Audience:
This program is designed for pharmacists and other health care professionals involved in the care and management of the elderly patients with atherothrombotic disease, where improvements in management and drug therapy can lead to optimal cardiovascular outcomes.

Disclosure of Financial Interest:
All faculty members participating in continuing medical education programs sponsored by the University of Kentucky College of Pharmacy Continuing Education Office are expected to disclose any real or perceived conflict of interest related to the content of their presentations. Detailed faculty disclosures will be included in the presentations at the meeting.

Accreditation Statement:
The University of Kentucky College of Pharmacy is approved by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This program has been assigned ACPE # 022-999-08-103-L01-P and will award 2.0 contact hours (0.2 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers. Statements of credit will indicate hours and CEUs based on participation and will be issued online at the conclusion of the activity. Successful completion includes signing in at registration, attending the entire session for which credit is claimed, completing the activity evaluation and requesting credit online at conclusion of the activity. The College complies with the Criteria for Quality for continuing education programming.

Disability Statement:
The University of Kentucky and Scius, LLC, fully comply with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Chris Orie at (908) 222-4928.

EEO Statement:
The University of Kentucky is an Equal Opportunity University.

Registration Information:
ONLINE: Register online here
PHONE: Call Chris Orie at (908) 222-4928, between the hours of 8:30 a.m. – 5:30 p.m. Eastern time, Monday through Friday.

Sponsored by the University of Kentucky College of Pharmacy in collaboration with Scius, LLC.

This activity is supported by an independent medical education grant from Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.

Tuesday, October 21

Registration and Breakfast: 6:00 a.m. – 7:00 a.m.
Satellite Symposium: 7:00 a.m. – 9:00 a.m.

Location:
Louisville Marriott Downtown
Kentucky Ballroom E, 1st floor

Program Overview:
Effective management of hypertensive crises—characterized by a severe elevation in blood pressure with target organ damage—relies on an integrated protocol involving clinical pharmacists who can provide expert guidance regarding pharmacologic treatment challenges specific to this condition. Acute hypertensive crises are most often seen in the emergency department, intensive care unit, and perioperative settings, where antihypertensive therapy is critical for quickly lowering blood pressure and preventing further morbidity and possible mortality. With adherence to appropriate antihypertensive therapy, the 10-year survival rate for patients with hypertensive crises may be up to 70%. Challenges exist in the management of acute hypertension, partly because of the lack of comprehensive practice guidelines for hypertensive urgencies and emergencies—it is estimated that acute hypertension management protocols are in place at less than 10% of U.S. hospitals, with physician preference still driving treatment decisions. Because of the potentially serious, often underrecognized burden of acute hypertension combined with the lack of treatment guidelines, clinical pharmacists require education on optimal approaches to manage hypertensive crises to assist physicians in optimizing outcomes.

Learning Objectives:

1. Describe the incidence and burden of acute hypertension in the hospital setting, including potential morbidity and mortality.
2. Outline the conditions and characteristics of patients most often presenting with acute hypertensive crises.
3. Summarize the benefits and limitations of current and emerging antihypertensive options for the management of acute hypertension.
4. Assist physicians in implementing protocols and patient-centered treatment decisions for acute hypertensive crises.

Agenda & Faculty:
Introduction

Acute Hypertension in the Hospital Setting—Early Diagnosis to Optimize Management
William E. Dager, Pharm.D., FCSHP
Pharmacist Specialist
University of California, Davis Medical Center
Clinical Professor of Pharmacy
UCSF School of Pharmacy
Associate Clinical Professor of Medicine
Division of Pulmonary/Critical Care Medicine
UC Davis School of Medicine
Sacramento, California

Advancing the Management of Acute Hypertensive Crises: Understanding the Evidence for Current and Emerging Therapies
Joseph F. Dasta, M.Sc., FCCM, FCCP
Professor Emeritus
The Ohio State University
Adjunct Professor of Pharmacy
College of Pharmacy at the University of Texas, Austin
Austin, Texas

Panel Discussion/Question & Answer Session
Co-moderated by William E. Dager, Pharm.D., FCSHP, and Joseph F. Dasta, M.Sc., FCCM, FCCP

Registration Information:
ONLINE: Register online at http://www.princetoncme.com
PHONE: Call North American Center for Continuing Medical Education at (609) 371-1137, between the hours of 8:30 a.m. and 4:30 p.m. Eastern time, Monday through Friday.

This program is supported by an educational grant from The Medicines Company.